Literature DB >> 18172003

BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells.

Gamal Badr1, Gwenoline Borhis, Eric A Lefevre, Nada Chaoul, Frederique Deshayes, Valérie Dessirier, Genevieve Lapree, Andreas Tsapis, Yolande Richard.   

Abstract

B-cell-activating factor of the TNF family, (BAFF), and a proliferation-inducing ligand (APRIL) regulate B-lymphocyte survival and activation. We report that BAFF, but not APRIL, increased the chemotactic response of primary human B cells to CCL21, CXCL12, and CXCL13. The BAFF-induced increase in B-cell chemotaxis was totally abolished by blockade of BAFF-R and was strongly dependent on the activation of PI3K/AKT, NF-kappaB, and p38MAPK pathways. BAFF had similar effects on the chemotaxis of naive and memory B cells in response to CCL21 but increased more strongly that of memory B cells to CXCL13 than that of naive B cells. Our findings indicate a previously unreported role for the BAFF/BAFF-R pair in mature B-cell chemotaxis. The synergy between CXCL13 and BAFF produced by stromal cells and follicular dendritic cells may have important implications for B-cell homeostasis, the development of normal B-cell areas, and for the formation of germinal center-like follicles that may be observed in various autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18172003     DOI: 10.1182/blood-2007-03-081232

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

1.  Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Authors:  William Stohl; Falk Hiepe; Kevin M Latinis; Mathew Thomas; Morton A Scheinberg; Ann Clarke; Cynthia Aranow; Frank R Wellborne; Carlos Abud-Mendoza; Douglas R Hough; Lilia Pineda; Thi-Sau Migone; Z John Zhong; William W Freimuth; W Winn Chatham
Journal:  Arthritis Rheum       Date:  2012-07

Review 2.  Innate signaling networks in mucosal IgA class switching.

Authors:  Alejo Chorny; Irene Puga; Andrea Cerutti
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

3.  Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of concept.

Authors:  N Roescher; J L Vosters; G Alsaleh; P Dreyfus; S Jacques; G Chiocchia; J Sibilia; P P Tak; J A Chiorini; X Mariette; Jacques-Eric Gottenberg
Journal:  Mol Ther       Date:  2013-12-05       Impact factor: 11.454

4.  Adipose tissue B2 cells promote insulin resistance through leukotriene LTB4/LTB4R1 signaling.

Authors:  Wei Ying; Joshua Wollam; Jachelle M Ofrecio; Gautam Bandyopadhyay; Dalila El Ouarrat; Yun Sok Lee; Da Young Oh; Pingping Li; Olivia Osborn; Jerrold M Olefsky
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

5.  Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.

Authors:  Daniel J Medina; Lauri Goodell; John Glod; Céline Gélinas; Arnold B Rabson; Roger K Strair
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

6.  TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.

Authors:  J L Vosters; N Roescher; G G Illei; J A Chiorini; P P Tak
Journal:  Oral Dis       Date:  2011-12-29       Impact factor: 3.511

Review 7.  Signaling mechanisms regulating B-lymphocyte activation and tolerance.

Authors:  Elias Hobeika; Peter J Nielsen; David Medgyesi
Journal:  J Mol Med (Berl)       Date:  2015-01-29       Impact factor: 4.599

8.  Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity.

Authors:  C K Wong; Purple T Y Wong; L S Tam; Edmund K Li; D P Chen; Christopher W K Lam
Journal:  J Clin Immunol       Date:  2009-09-23       Impact factor: 8.317

9.  Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis.

Authors:  Queenie Lai Kwan Lam; Otis King Hung Ko; Bo-Jian Zheng; Liwei Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-26       Impact factor: 11.205

10.  A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Authors:  Daniel J Wallace; William Stohl; Richard A Furie; Jeffrey R Lisse; James D McKay; Joan T Merrill; Michelle A Petri; Ellen M Ginzler; W Winn Chatham; W Joseph McCune; Vivian Fernandez; Marc R Chevrier; Z John Zhong; William W Freimuth
Journal:  Arthritis Rheum       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.